New York esophageal squamous cell carcinoma 1 peptide–Major Histocompatibility Complex (NY-ESO-1 pMHC)

The NY-ESO-1 peptide–MHC complex is a highly specific tumor target formed by the presentation of intracellular cancer-testis antigen 1 (NY-ESO-1) fragments on the surface of malignant cells [4, 14]. NY-ESO-1, encoded by the CTAG1B gene, is a prototypical cancer-testis antigen with expression restricted to germ cells in the testis and placenta—tissues that lack MHC class I expression and are thus protected from T-cell attack [4, 10]. In various cancers, including synovial sarcoma, myxoid/round-cell liposarcoma, and melanoma, NY-ESO-1 is aberrantly re-expressed and processed into peptides, such as the immunodominant SLLMWITQC epitope, which are then presented by Major Histocompatibility Complex (MHC) molecules like HLA-A*02:01 [9, 14, 18]. This complex serves as a critical recognition site for the adaptive immune system and is the primary target for engineered T-cell receptor (TCR-T) therapies and TCR-like antibodies [6, 11, 13]. Therapeutic agents like letetresgene autoleucel utilize high-affinity TCRs to redirect autologous T cells to recognize and eliminate tumor cells displaying this pMHC complex [22, 23, 31]. Because of its high tumor specificity and lack of expression in essential healthy tissues, the NY-ESO-1 pMHC complex is considered one of the safest and most promising targets for solid tumor immunotherapy [5, 14, 45].

Other names

NY-ESO-1 peptide–MHC complexCTAG1B peptide-MHC complexNY-ESO-1/HLA-A*02:01 complexNY-ESO-1 pMHCNY-ESO-1 peptide–MHC complex on tumor cellsCancer/testis antigen 1B peptide–MHC complexNew York esophageal squamous cell carcinoma 1 peptide–MHC complex

T-cell receptor (TCR) binding and activation, Cytotoxic T-lymphocyte (CTL) mediated lysis, Cytokine release (IFN-gamma, TNF-alpha), and Induction of apoptosis in target tumor cells.